The results of this study represent an essential contribution to this emerging field of research and may be vital in paving the way for novel therapeutic strategies targeting the COX-2/PGE2/IL-22 axis in depression and other neuropsychiatric disorders. Here, IL22 is linked to depressive symptom measurement.